They also claim that Leo canceled P's interim analysis because it's bad. If Leo received the interim analysis, he has to release it regardless according to the Regulation Fair Disclosure. The fact that Leo hasn't released the interim analysis means he doesn't have it.
When Leo blogs about a drug or adds sites to a trial, the result turns out to be positive. I expect the trend to continue with B-OM and P.
(1)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links